

Valentina Di iorio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4971812/publications.pdf>

Version: 2024-02-01

16
papers

364
citations

933447

10
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

544
citing authors

#	ARTICLE	IF	CITATIONS
1	Peptide receptor radionuclide therapy with ¹⁷⁷ Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and ¹⁸ F-FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1040-1046.	6.4	77
2	Feasibility and utility of re-treatment with ¹⁷⁷ Lu-DOTATATE in GEP-NENs relapsed after treatment with ⁹⁰ Y-DOTATOC. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1955-1963.	6.4	62
3	Dosimetry and safety of ¹⁷⁷ Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3008-3017.	6.4	37
4	Dosimetry of ¹⁷⁷ Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol. <i>Molecules</i> , 2019, 24, 621.	3.8	34
5	Reduction of ⁶⁸ Ga-PSMA renal uptake with mannitol infusion: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2189-2194.	6.4	30
6	Combined use of ¹⁷⁷ Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3260-3267.	6.4	29
7	¹⁷⁷ Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 152-160.	6.4	20
8	Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of ²²⁵ Ac-PSMA (Prostate-Specific Membrane Antigen). <i>Frontiers in Oncology</i> , 2020, 10, 531660.	2.8	15
9	Circulating androgen receptor gene amplification and resistance to ¹⁷⁷ Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. <i>British Journal of Cancer</i> , 2021, 125, 1226-1232.	6.4	13
10	⁶⁸ Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy. <i>Biomedicine</i> , 2020, 8, 536.	3.2	11
11	Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR). <i>Supportive Care in Cancer</i> , 2017, 25, 111-117.	2.2	8
12	A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	8
13	Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 1478.	2.8	7
14	Production and Quality Control of [¹⁷⁷ Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials. <i>Molecules</i> , 2022, 27, 4143.	3.8	7
15	SUV95th as a Reliable Alternative to SUVmax for Determining Renal Uptake in [⁶⁸ Ga] PSMA PET/CT. <i>Molecular Imaging and Biology</i> , 2020, 22, 1070-1077.	2.6	4
16	Theragnostic in neuroendocrine tumors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 65, .	0.7	2